11 三月 2019

Arvelle Therapeutics raises USD 180 million in Series A financing

A global syndicate of investors led by LSP and including NovaQuest, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners supported new company Arvelle Therapeutics with a USD 180 million financing to acquire the exclusive rights from Korean SK Biopharmaceuticals to develop and commercialise cenobamate in Europe.

VISCHER advised Arvelle Therapeutics as Swiss Counsel. The VISCHER team included Dr. Adrian Dörig (Partner, Banking & Finance), Seraina Jenny-Tsering (Managing Associate, Banking & Finance), Ruben Masar (Senior Associate, Corporate) and Christoph Niederer (Partner, Tax).

分享文章至:

包含的服务:

与我们的作者取得联系,受益于他们的专业知识:

partner-Adrian-0

Adrian Dörig

adrian.doerig@vischer.com

+41 58 211 34 89

partner-Ruben-1

Ruben Masar

ruben.masar@vischer.com

+41 58 211 33 38

partner-Christoph-2

Christoph Niederer

christoph.niederer@vischer.com

+41 58 211 34 37

我们的
新闻通讯